Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Just two weeks after announcing a development collaboration deal with Onyx Pharmaceuticals on JAK2 inhibitors, Singapore-based S*BIO announced it inked a licensing deal Jan. 21 with San Diego-based Tragara Pharmaceuticals covering its multi-kinase inhibitor SB1317 for leukemia
Advertisement

Related Content

COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Singapore's S*BIO Initiates Phase II Trials In Canada; Picks Up New Investor
Singapore's S*BIO Initiates Phase II Trials In Canada; Picks Up New Investor
Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors
Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors
Deals Of The Week: GSK/UCB, Myriad/Panacos, Tragara/S*BIO
Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors
Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors
S*BIO CEO Jan-Anders Karlsson On Development Success In Singapore: An Interview With PharmAsia News
Advertisement
UsernamePublicRestriction

Register

SC069893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel